Loading
Pasithea Therapeutics Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 Jun 2026.
Pasithea Therapeutics Corp.: what insiders have been doing
Every trade that managers of Pasithea Therapeutics Corp. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 6 insiders have disclosed 6 filings since 18 October 2025.
Not one open-market sale was filed. On the buying side, 4 insiders reported 4 purchases totalling €129k. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 2 senior executives, 1 major shareholder and 1 chief executive among the declarants. Biggest ticket of the year: €86k, bought by Steinman Lawrence and made public on 1 December 2025.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 22 June 2026, 117 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 6 filings here. Since 2021, the database holds 11 purchases and 1 sale by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€537,076
11 ops. · all time
Sell Volume
€714
1 ops. · all time
Who traded when
BuySaleTiago Marques1 buy1 sale
Coastlands Capital LP1 buy
Lawrence Steinman1 buy
Simon Dumesnil1 buy
Since the insiders bought
- -10.2%Entry US$0.57 · Close at T+90 US$0.51
- -31.6%Entry US$1.19 · Close at T+90 US$0.81
- -31.6%Entry US$1.19 · Close at T+90 US$0.81
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.42
Analyst consensus
1 analystsUS$3.00Target US$3.00(+614%)US$3.00
Income statement
Gross profitUS$373.4k
EBITDA-US$20.2M
Net income-US$20.4M0.0% margin
Valuation
PER (forward)-0.9x
P/Book0.3x
Beta0.34
Balance sheet & cash
Market capUS$14M
Free Cash Flow-US$15.2M
Profitability & ownership
ROE-65.5%
ROA-36.0%
% insiders1.1%
% institutions63.2%
Last declaration on 22 June 2026
Declarations28 total
100,000 sharesCommon StockSEC:0001104659-26-076184:0
Canonical exit: 15 Sept 2026 (T+90)
133,333 shares@ US$0.7567.0% of flowCommon StockSEC:0001213900-25-116309:0
Canonical exit: 26 Feb 2026 (T+90)
26,667 shares@ US$0.75100.0% of flowCommon StockSEC:0001213900-25-116306:0
33,333 shares@ US$0.7570.6% of flowCommon StockSEC:0001213900-25-116301:0
Canonical exit: 26 Feb 2026 (T+90)
33,333 shares@ US$0.7567.5% of flowCommon StockSEC:0001213900-25-116299:0
Canonical exit: 26 Feb 2026 (T+90)
33,333 shares@ US$0.75100.0% of flowCommon StockSEC:0001213900-25-116296:0
960 shares@ US$0.8252.3% of flowCommon StockSEC:0001213900-25-043621:0
750 shares@ US$5.61100.0% of flowCommon StockSEC:0001213900-24-053005:0
30,000 shares@ US$0.4319.3% of flowCommon StockSEC:0001493152-23-020333:0
Canonical exit: 31 Aug 2023 (T+90)
5,000 shares@ US$1.0015.9% of flowCommon StockSEC:0001213900-22-075490:0
5,000 shares@ US$0.983.7% of flowCommon StockSEC:0001213900-22-075491:0
5,000 shares@ US$0.993.8% of flowCommon StockSEC:0001213900-22-074585:0
10,000 shares@ US$1.0732.5% of flowCommon StockSEC:0001213900-22-073502:0
5,000 shares@ US$1.104.2% of flowCommon StockSEC:0001213900-22-066554:0
600 shares@ US$1.082.2% of flowCommon StockSEC:0001213900-22-065571:0
1,000 shares@ US$1.11100.0% of flowCommon StockSEC:0001209191-22-054100:0
Canonical exit: 15 Jan 2023 (T+90)
1,000 shares@ US$1.140.9% of flowCommon StockSEC:0001213900-22-064401:0
57,647 shares@ US$1.18921.8% of flowCommon StockSEC:0001209191-22-051650:0
Canonical exit: 27 Dec 2022 (T+90)
55,646 shares@ US$1.125519.4% of flowCommon StockSEC:0001209191-22-048789:0
Canonical exit: 30 Nov 2022 (T+90)
5,000 shares@ US$1.16811.8% of flowCommon StockSEC:0001209191-22-048135:0
Canonical exit: 27 Nov 2022 (T+90)
54,644 shares@ US$1.2982100.0% of flowCommon StockSEC:0001209191-22-047714:0
Canonical exit: 17 Nov 2022 (T+90)
155,773 shares@ US$1.208757.0% of flowCommon StockSEC:0001493152-22-023502:0
Canonical exit: 15 Nov 2022 (T+90)
5,000 shares@ US$1.023.8% of flowCommon StockSEC:0001213900-22-036296:0
5,000 shares@ US$1.003.7% of flowCommon StockSEC:0001213900-22-035201:0
2,900 shares@ US$0.9939.0% of flowCommon StockSEC:0001213900-22-034643:0
25 of 28 declarations
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. is a U.S.-listed biotechnology company quoted on the NASDAQ under the symbols KTTA and KTTAW. Its principal executive offices are in Miami Beach, Florida, United States. The company was incorporated in 2020 and completed its IPO in September 2021. Over time, Pasithea shifted away from an earlier focus on central nervous system and psychiatric/neurological programs toward a more concentrated development strategy centered on precision oncology, RASopathies, and selected rare genetic diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1841330/000121390025110093/ea0264188-10q_pasithea.htm?utm_source=openai))
Pasithea’s lead asset is PAS-004, a next-generation oral macrocyclic MEK inhibitor. The program is being developed primarily for neurofibromatosis type 1 (NF1), especially plexiform neurofibromas, and more broadly for MAPK-pathway-driven tumors and other RAS/MAPK-related indications. The company has also described potential applications in patients with solid tumors carrying documented RAS, NF1 or RAF mutations, and in patients who have failed prior BRAF/MEK inhibition. In practical terms, Pasithea is now a single-asset clinical-stage biotech, so the investment case is driven almost entirely by PAS-004 clinical and regulatory execution. ([ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/116/pasithea-therapeutics-announces-completion-of-enrollment?utm_source=openai))
Read moreShow less
From a competitive standpoint, Pasithea operates in a highly crowded and capital-intensive segment of biotechnology. Larger pharma and biotech peers have meaningful advantages in funding, clinical infrastructure, and regulatory experience. Pasithea’s differentiation is based on PAS-004’s macrocyclic chemistry and the company’s effort to build a profile around tolerability, pharmacokinetics, and target engagement. However, the company remains a development-stage micro-cap with no established commercial revenue base, which means the equity story is inherently high risk and highly dependent on future clinical readouts. ([ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/131/pasithea-therapeutics-announces-positive-pas-004-tablet?utm_source=openai))
Recent milestones have been important for the stock narrative. In 2025, Pasithea reported opening European clinical trial sites, advancing its Phase 1 enrollment, and releasing positive interim pharmacodynamic and pharmacokinetic updates, alongside public financings to support ongoing development. In April 2026, the company announced that the FDA granted Rare Pediatric Disease Designation to PAS-004 for NF1, a potentially meaningful regulatory signal that may enhance the program’s strategic optionality if development continues to progress. For investors, Pasithea should be viewed as a speculative clinical-stage biotech with significant upside potential in the event of positive data, but also with financing dilution and execution risk typical of early-stage drug developers. ([ir.pasithea.com](https://ir.pasithea.com/news-events/press-releases/detail/111/pasithea-therapeutics-announces-opening-of-european?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
